Wrapmanager Inc. Sells 3,996 Shares of Gilead Sciences, Inc. $GILD

Wrapmanager Inc. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 43.0% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 5,304 shares of the biopharmaceutical company’s stock after selling 3,996 shares during the quarter. Wrapmanager Inc.’s holdings in Gilead Sciences were worth $589,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in GILD. First Heartland Consultants Inc. increased its stake in Gilead Sciences by 3.7% in the 3rd quarter. First Heartland Consultants Inc. now owns 4,849 shares of the biopharmaceutical company’s stock valued at $538,000 after buying an additional 175 shares during the last quarter. First American Trust FSB bought a new position in shares of Gilead Sciences in the third quarter valued at approximately $201,000. Mufg Securities Americas Inc. increased its position in shares of Gilead Sciences by 21.4% during the third quarter. Mufg Securities Americas Inc. now owns 33,460 shares of the biopharmaceutical company’s stock valued at $3,714,000 after acquiring an additional 5,891 shares during the last quarter. AXQ Capital LP bought a new stake in Gilead Sciences during the third quarter worth $1,527,000. Finally, First Financial Bankshares Inc boosted its position in Gilead Sciences by 1.6% in the third quarter. First Financial Bankshares Inc now owns 7,446 shares of the biopharmaceutical company’s stock worth $827,000 after purchasing an additional 115 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on GILD. Argus raised their target price on Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Wolfe Research increased their target price on shares of Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, February 12th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Finally, Wall Street Zen lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Twenty-three equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $155.44.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $149.83 on Tuesday. The firm has a market capitalization of $185.89 billion, a P/E ratio of 22.13, a PEG ratio of 2.01 and a beta of 0.36. Gilead Sciences, Inc. has a one year low of $93.37 and a one year high of $157.29. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.68 and a quick ratio of 1.31. The business has a fifty day moving average price of $134.07 and a 200-day moving average price of $124.08.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. During the same quarter in the prior year, the firm posted $1.90 EPS. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. Gilead Sciences’s dividend payout ratio (DPR) is 48.45%.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Arcellx for an implied equity value of about $7.8 billion to gain full control of the Anito‑cel CAR‑T program — accelerates Gilead’s oncology pipeline and could deliver a near‑term product if regulatory timelines hold. Gilead Sciences to Acquire Arcellx — BusinessWire
• Positive Sentiment: Analysts reaffirming coverage and bullish price targets support the stock’s fundamental story — Needham reiterated a Buy with a $170 target, signaling continued institutional support. Needham reaffirmed buy on GILD — Benzinga
• Neutral Sentiment: Gilead announced management will present at multiple investor conferences in early March, providing more opportunities to detail the Arcellx rationale and upcoming catalysts. Gilead to present at investor conferences — BusinessWire
• Neutral Sentiment: Arcellx’s program has regulatory momentum (BLA acceptance reports), which underpins the strategic rationale but leaves remaining execution and integration risk for Gilead. Arcellx BLA accepted — TipRanks
• Negative Sentiment: A plaintiff‑side law firm has opened an investigation into the adequacy of the Arcellx sale process and price, introducing potential legal/transactional risk and distraction. KSF investigating Arcellx sale — BusinessWire
• Negative Sentiment: The deal price implies a ~68–80% premium to recent Arcellx levels, raising concerns about Gilead overpaying and the impact on capital allocation/valuation. Market participants are weighing strategic upside vs near‑term EPS/valuation dilution. Gilead to acquire Arcellx for up to $7.8B — Reuters
• Negative Sentiment: Broader market weakness in the session (Dow/tech softness) likely pressured Gilead alongside stock‑specific headwinds. Dow posts one‑day drop — Yahoo Finance

Insider Activity

In related news, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. This represents a 35.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the sale, the chief financial officer owned 150,503 shares in the company, valued at $18,709,027.93. This represents a 1.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 319,891 shares of company stock worth $45,091,556 in the last three months. Insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.